Crossmark

Strategy to detect pre-existing immunity to AAV gene therapy

Crossref DOI link: https://doi.org/10.1038/gt.2017.95

Published Online: 2017-11-06

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Falese, L https://orcid.org/0000-0002-3976-8127
Sandza, K https://orcid.org/0000-0003-2499-3708
Yates, B

Triffault, S

Gangar, S

Long, B

Tsuruda, L

Carter, B

Vettermann, C

Zoog, S J

Fong, S
License Information

Text and Data Mining valid from 2017-11-06
More Information

Article History

Received: 12 May 2017

Revised: 1 September 2017

Accepted: 24 October 2017

First Online: 6 November 2017

Competing interests

: KS, BY, BL, BC, CV, SJZ and SF are employees of BioMarin Pharmaceutical, Inc., and ST is an employee of GenoSafe. During research and manuscript development, LF and LT were employees of BioMarin Pharmaceutical, Inc., and SG was an employee of Eurofin BioAnalytical Services.